Lenalidomide
CC-5013-CLL-002
Phase 3 small_molecule completed
Quick answer
Lenalidomide for B-cell Chronic Lymphocytic Leukemia is a Phase 3 program (small_molecule) at Celgene Europe Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Celgene Europe Limited
- Indication
- B-cell Chronic Lymphocytic Leukemia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed